Utilization of macrophages in anticancer therapy: The macrophage network theory

Anticancer Research

Volumn 24, Issue 5 C, 2004, Pages 3311-3320

  Kohchi, Chie ^a,b   Inagawa, Hiroyuki ^a,b,c   Hino, Mami ^a   Oda, Mutsumi ^a   Nakata, Kazue ^a   Yoshida, Aya ^d   Hori, Hitoshi ^d   Terada, Hiroshi ^b   Makino, Kimiko ^b   Takiguchi, Kunio ^e   Soma, Gen Ichiro ^a,b  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c NATIONAL FISHERIES UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Immune therapy; Innate immunity; Lipopolysaccharide; LPS tolerance; Macrophage; Review

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER; CELL KILLING; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOKINE ACTIVATED KILLER CELL; MACROPHAGE ACTIVATION; MACROPHAGE NETWORK THEORY; NONHUMAN; PRIORITY JOURNAL; THEORY; TISSUE SPECIFICITY; TUMOR ASSOCIATED LEUKOCYTE; UTILIZATION REVIEW;

ANIMALS; HUMANS; IMMUNOTHERAPY; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; NEOPLASMS;

EID: 6344291424     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. Kuroki M, Shibaguchi H, Imakiire T, Uno K, Shirota K, Higuchi T, Shitama T, Yamada H, Hirose Y and Nagata A: Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens. Anticancer Res 23: 4377-4381, 2003.
2. Mami-Chouaib F, Echchakir H, Dorothee G, Vergnon I and Chouaib S: Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev 188: 114-121, 2002.
3. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF and Eberlein TJ: HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54: 3387-3390, 1994.
4. Boon T, Coulie PG and Van den Eynde B: Tumor antigens recognized by T cells. Immunol Today 18: 267-268, 1997.
5. Van den Eynde BJ and van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol 9: 684-693, 1997.
6. Huffman DM, Gitlitz BJ, Belldegrun A and Figlin RA: Adoptive cellular therapy. Semin Oncol 27: 221-233, 2000.
7. Conrad C and Nestle FO: Dendritic cell-based cancer therapy. Curr Opin Mol Ther 5: 405-412, 2003.
8. Wiethe C, Dittmar K, Doan T, Lindenmaier W and Tindle R: Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol 770: 2912-2922, 2003.
9. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18: 175-182, 1997.
10. Gitlitz BJ, Belldegrun AS and Figlin RA: Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol 19: 141-147, 2001.
11. Wimer BM: The ideal biological response modifier. Mol Biother 1: 311-317, 1989.
12. Palapattu GS and Reiter RE: Monoclonal antibody therapy for genitourinary oncology: promise for the future. J Urol 168: 2615-2623, 2002.
13. Haupt K, Roggendorf M and Mann K: The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp Biol Med (Maywood) 227: 227-237, 2002.
14. Hodge JW, Grosenbach DW and Schlom J: Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. Cancer Detect Prev 26: 275-291, 2002.
15. Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ and Deisseroth AB: An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 100: 15101-15106, 2003.
16. Chang CC, Campoli M and Ferrone S: HLA class I defects in malignant lesions: what have we learned? Keio J Med 52: 220-229, 2003.
17. Vercelli D: Innate immunity: sensing the environment and regulating the regulators. Curr Opin Allergy Clin Immunol 3: 343-346, 2003.
18. Ross JA and Auger MJ: The biology of the macrophage. In: The Macrophage. (Burke B and Lewis EC, eds). New York, Oxford University Press Inc. 2002, pp 1-57.
19. Paglia P and Colombo MP: Macrophage as antigen-presenting cells: relationship to dendritic cells and use in vaccination studies. In: The Macrophage. (Burke B and Lewis EC, eds).New York, Oxford University Press Inc. 2002, pp 103-125.
20. Ohno S, Suzuki N, Ohno Y, Inagawa H, Soma G and Inoue M: Tumor-associated macrophages: foe or accomplice of tumors? Anticancer Res 23: 4395-4409, 2003.
21. Medzhitov R and Janeway C Jr: The Toll receptor family and microbial recognition. Trends Microbiol 8: 452-456, 2000.
22. Takeda K and Akira S: TLR signaling pathways. Semin Immunol 16: 3-9, 2004.
23. Mungrue IN, Bredt DS, Stewart DJ and Husain M: From molecules to mammals: what's NOS got to do with it? Acta Physiol Scand 779: 123-135, 2003.
24. Ziegler-Heitbrock HW: Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm 45: 13-26, 1995.
25. Beutler B, Tkacenko V, Milsark I, Krochin N and Cerami A: Effect of gamma Interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype. J Exp Med 164: 1791-1796, 1986.
26. Mita Y, Dobashi K, Shimizu Y, Nakazawa T and Mori M: Toll-like receptor 2 and 4 surface expressions on human monocytes are modulated by interferon-gamma and macrophage colony-stimulating factor. Immunol Lett 78: 97-101, 2001.
27. Suzuki M, Hisamatsu T and Podolsky DK: Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-like receptor 4-MD-2 complex. Infect Immun 77: 3503-3511, 2003.
28. Tamai R, Sugawara S, Takeuchi O, Akira S and Takada H: Synergistic effects of lipopolysaccharide and interferon-gamma in inducing interleukin-8 production in human monocytic THP-1 cells is accompanied by up-regulation of CD14, Toll-like receptor 4, MD-2 and MyD88 expression. J Endotoxin Res 9: 145-153, 2003.
29. Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M, Nakanishi K, Kimoto M, Miyake K, Takeda K and Akira S: Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol 164: 3476-3479, 2000.
30. Tanabe Y, Kitahara-Tanabe N, Mizuno D and Soma GI: Enhanced production of tumour necrosis factor alpha (TNF-alpha) by its precursor on the cell surface of primed THP-1 cells. Cytokine 6: 337-348, 1994.
31. Soma IG, Nishizawa T, Inagawa H, Tanabe Y, Noguchi K, Goto S, Takagi K and Mizuno D: Bidirectional feedback regulation on 17 kD tumor necrosis factor (TNF) production by 26 kD membrane-bound TNF precursor. J Inflamm 47: 52-60, 1995.
32. Tanabe Y, Kohchi C, Kitahara-Tanabe N, Mizuno D and Soma G: Involvement of 26-kDa membrane-bound tumour necrosis factor precursor in bidirectional feedback regulation on 17-kDa tumour necrosis factor production after stimulation by lipopolysaccharide. Cytokine 10: 82-92, 1998.
33. Watts AD, Hunt NH, Wanigasekara Y, Bloomfield G, Wallach D, Roufogalis BD and Chaudhri G: A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. Embo J 18: 2119-2126, 1999.
34. Domonkos A, Udvardy A, Laszlo L, Nagy T and Duda E: Receptor-like properties of the 26 kDa transmembrane form of TNF. Eur Cytokine Netw 12: 411-419, 2001.
35. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K et al: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83: 793-802, 1995.
36. Guha M and Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 13: 85-94, 2001.
37. Bancroft GJ, Kelly JP, Kaye PM, McDonald V and Cross CE: Pathways of macrophage activation and innate immunity. Immunol Lett 43: 67-70, 1994.
38. Smith PD, Smythies LE, Mosteller-Barnum M, Sibley DA, Russell MW, Merger M, Sellers MT, Orenstein JM, Shimada T, Graham MF and Kubagawa H: Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. J Immunol 767: 2651-2656, 2001.
39. Nishizawa T, Inagawa H, Oshima H, Okutomi T, Tsukioka D, Iguchi M, Soma G and Mizuno D: Homeostasis as regulated by activated macrophage. I. Lipopolysaccharide (LPS) from wheat flour: isolation, purification and some biological activities. Chem Pharm Bull (Tokyo) 40: 479-483, 1992.
40. Asis CA Jr and Adachi K: Isolation of endophytic diazotroph Pantoea agglomerans and nondiazotroph Enterobacter asburiae from sweetpotato stem in Japan. Lett Appl Microbiol 38: 19-23, 2004.
41. Nunes C, Usall J, Teixido N, Fons E and Vinas I: Post-harvest biological control by Pantoea agglomerans (CPA-2) on Golden Delicious apples. J Appl Microbiol 92: 247-255, 2002.
42. Tsukioka D, Nishizawa T, Miyase T, Achiwa K, Suda T, Soma G and Mizuno D: Structural characterization of lipid A obtained from Pantoea agglomerans lipopolysaccharide. FEMS Microbiol Lett 149: 239-244, 1997.
43. Inagawa H, Saitoh F, Iguchi M, Nishizawa T, Okutomi T, Morikawa A, Soma GI and Mizuno D: Homeostasis as regulated by activated macrophage. III. Protective effect of LPSw (lipopolysaccharide (LPS) of wheat flour) on gastric ulcer in mice as compared with those of other LPS from various sources. Chem Pharm Bull (Tokyo) 40: 998-1000, 1992.
44. Okutomi T, Nishizawa T, Inagawa H, Morikawa A, Takeuchi S, Soma GI and Mizuno D: Homeostasis as regulated by activated macrophage. IV. Analgesic effect of LPSw, a lipopolysaccharide of wheat flour. Chem Pharm Bull (Tokyo) 40: 1001-1003, 1992.
45. Iguchi M, Inagawa H, Nishizawa T, Okutomi T, Morikawa A, Soma GI and Mizuno D: Homeostasis as regulated by activated macrophage. V. Suppression of diabetes mellitus in non-obese diabetic mice by LPSw (a lipopolysaccharide from wheat flour). Chem Pharm Bull (Tokyo) 40:1004-1006, 1992.
46. Suzuki Y, Kobayashi A, Nishizawa T, Inagawa H, Morikawa A, Soma G and Mizuno D: Homeostasis as regulated by activated macrophage. VI. Protective effect of LPSw (a lipopolysaccharide from wheat flour) against acute infection by Toxoplasma gondii in mice. Chem Pharm Bull (Tokyo) 40: 1266-1267, 1992.
47. Okutomi T, Nishizawa T, Inagawa H, Takano T, Morikawa A, Soma G and Mizuno D: Homeostasis as regulated by activated macrophage. VII. Suppression of serum cholesterol level by LPSw (a lipopolysaccharide from wheat flour) in WHHL (Watanabe heritable hyperlipidemic) rabbit. Chem Pharm Bull (Tokyo) 40: 1268-1270, 1992.
48. Kawashima K, Endo H, Nishizawa T, Inagawa H, Okutomi T, Morikawa A, Soma G and Mizuno D: Homeostasis as regulated by activated macrophage. VIII. LPSw (a lipopolysaccharide from wheat flour) can regulate bone resorption of chick embryo. Chem Pharm Bull (Tokyo) 40: 1271-1273, 1992.
49. Suzuki J, Nishizawa T, Inagawa H, Okutomi T, Morikawa A, Soma G and Mizuno D: Homeostasis as regulated by activated macrophage. IX. Enhancement effect of LPSw (a lipopolysaccharide from wheat flour) on hen egg-laying and breaking strength of eggshell. Chem Pharm Bull (Tokyo) 40: 1274-1276, 1992.
50. Okutomi T, Nishizawa T, Inagawa H, Soma G, Minami M, Satoh M and Mizuno D: Inhibition of morphine dependence by a lipopolysaccharide from Pantoea agglomerans. Eur Cytokine Netw 3: 417-420, 1992.
51. Mizuno D and Soma G: Oral or percutaneous administration of lipopolysaccharide of small molecular size may cure various intractable diseases: a new version of Coley's toxin. Mol Biother 4: 166-169, 1992.
52. Suzuki T, Funada M, Sugano Y, Misawa M, Okutomi T, Soma G and Mizuno D: Effects of a lipopolysaccharide from Pantoea agglomerans on the cocaine-induced place preference. Life Sci 54: PL75-80, 1994.
53. Kamei J, Iwamoto Y, Suzuki T, Misawa M, Kasuya Y, Nagase H, Okutomi T, Soma G and Mizuno D: Antinociceptive effect of lipopolysaccharide from Pantoea agglomerans on streptozotocin-induced diabetic mice. Eur J Pharmacol 257: 95-98, 1994.
54. Kamei J, Iwamoto Y, Suzuki T, Misawa M, Kasuya Y, Okutomi T, Soma G and Mizuno D: Suppression of hyperalgesia in streptozotocin-induced diabetic mice by a lipopolysaccharide from Pantoea agglomerans. Biol Pharm Bull 17: 632-634, 1994.
55. Inagawa H, Nishizawa T, Noguchi K, Minamimura M, Takagi K, Goto S, Soma G and Mizuno D: Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system. Anticancer Res 17: 2153-2158, 1997.
56. Iwamoto I, Goto S, Kera J, Soma G, Takeuchi S and Nagata Y: Mechanistic analysis of high antitumor effect of intradermal administration of lipopolysaccharide from Pantoea agglomerans. Med Oncol 13: 103-109, 1996.
57. Goto S, Sakai S, Kera J, Suma Y, Soma GI and Takeuchi S: Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunol Immunother 42: 255-261, 1996.
58. Lucas M, Stuart LM, Savill J and Lacy-Hulbert A: Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J Immunol 171: 2610-2615, 2003.
59. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G and Nagasue N: The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 23: 5015-5022, 2003.
60. Ohno S, Ohno Y, Suzuki N, Inagawa H, Kohchi C, Soma G-I and Inoue M: Functional differences depending on histological localization of tumor-associated macrophages in endometrial cancer. Anticancer Res 24: in press, 2004.
61. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR and Girkontaite I: Immunosuppressive effects of apoptotic cells. Nature 390: 350-351, 1997.
62. Chomarat P, Dantin C, Bennett L, Banchereau J and Palucka AK: TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol 171: 2262-2269, 2003.
63. Inagawa H, Ohshiro S, Nishizawa T, Goto S, Soma G and Mizuno D: Augmentation of antitumor effect of endogenously induced tumor necrosis factor by cyclophosphamide. Anticancer Res 17: 55-60, 1997.
64. Inagawa H, Nishizawa T, Honda T, Nakamoto T, Takagi K and Soma G: Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res 18: 3957-3964, 1998.
65. Takiguchi K, Nakamoto T, Inagawa H, Kohchi C, Nishizawa T, Nagasue N and Soma G-I: Profile of cytokine produced in tumor tissue after administration of cyclophosphamide in a combination therapy with tumor necrosis factor. Anticancer Res 24: 1823-1828, 2004.
66. Heale J-P and Speert DP: Macrophages in bacterial infection. In: The Macrophage. (Burke B and Lewis CE, eds). New York, Oxford University Inc. 2002, pp 212-237.
67. Kreutz M, Fritsche J and Andreesen R: Macrophage in tumor biology. In: The Macrophage. (Burke B and Lewis CE, eds). New York, Oxford University Press Inc. 2002, pp 457-474.